Our Company
AIKO Biotechnology, Inc. ("AIKO") is an early stage drug discovery company founded to characterize and validate therapeutic candidates for the management of pain, addiction and adverse side effects resulting from prescription opioid pain reliever use.
AIKO's lead drug candidates will significantly increase the safety and efficacy of opioids that are used by millions of pain sufferers, with the ultimate goal to provide safe analgesics with minimal side effects while eliminating the addictive and abuse potential of the most powerful pain relievers.
|
Our Compounds
AIKO-150 is the only known candidate drug suitable for co-formulation with an opioid analgesic that will confer both abuse resistance and limited side effects, particularly constipation.
AIKO-160 represents an ideal candidate for combination products with opioid analgesics, or as stand-alone therapy for peripheral opioid side effects, such as constipation and post operative ileus.
AIKO compounds are also well suited as stand-alone therapy for management of opioid overdose and addiction to narcotics, alcohol and nicotine.
|
Our News
AIKO Biotechnology receives a Development Award from the Maine Technology Institute for Novel Pain and Addiction Management Therapeutics for further validation of three lead compounds.
More...
AIKO Biotechnology announces its receipt of a Small Business Innovation Research Award from the National Institutes of Health, National Institute of Drug Abuse to fully evaluate and prove the concept for its second lead compound to treat the side effects from pain.
More...
|
